milvexian section,asundexian
bayer
['factor xi', 'pacific-ami']
pacific-ami phase 2b trial: asudexian inhibits &gt;90% of factor xia activity. in ami patients on dapt, asudexian resulted in no increase in bleeding at any dose vs placebo. no fatal bleeding in trial. no difference in ischemic outcomes #esccongress #esc2022 
Non-Profit Founder/Leader | ?? Doc | Artist | Scientist | Educator | News Anchor https://t.co/usmuA3tKft | RT ? endorse | Disclaimer: https://t.co/bwmE2O3U5W